StockData
Vivani Medical, Inc. logo

Vivani Medical, Inc. (VANI) stock

VANINasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$1.13−0.02 (-1.74%)

Close on Nov 11, 2026Market cap $101.93MP/E –Yield –

Vivani Medical, Inc. reported revenue of $0 for fiscal 2025. Free cash flow was -$26.50M. At the latest close the market valued the company at $101.93M.

Revenue
$0
FY2025
Operating income
-$27.23M
TTM Q2 2026
Free cash flow
-$26.50M
TTM Q2 2026
EPS, diluted
-$0.35
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026

Valuation

Market cap
$101.93M
P/E ratio
–
Price to sales
–
Price to book
5.37
Dividend yield
–
Free cash flow yield
-26.00%

Fundamentals

Revenue
$0
Net income
-$26.31M
EPS, diluted
-$0.35
Free cash flow
-$26.50M
Book value per share
$0.22
Diluted shares
87M

Trading

Next earnings
Nov 12, 2026 (estimated, before the open)
Previous close
$1.15
Open
$1.15
Day's range
$1.11 – $1.16
Volume
136,732
Average volume (20 days)
192,462
Beta (5 years)
1.14
52-week range
$0.92 – $1.66
RSI (14 days)
48.6
Volatility (1 year)
63.1%
Relative volume
0.36×
WACC
10.6%

Market cap history

Month-end market cap since 2014, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.

PeriodVANIS&P 500DifferenceVANI per yearS&P 500 per year
1 month-9.6%-2.4%−7.2 pts
3 months-18.7%-1.2%−17.6 pts
Year to date-8.1%+12.3%−20.4 pts
1 year-21.0%+12.4%−33.4 pts
3 years+18.7%+78.8%−60.1 pts+5.9%+21.4%
5 years-85.9%+75.2%−161.1 pts-32.5%+11.9%
10 years-97.8%+311.1%−408.9 pts-31.8%+15.2%

Fourteen years at a glance

Fiscal years 2012 to 2025 and trailing twelve months, USD

Revenue

–

Gross profit

–

Operating income

-$27.23M

Net income

-$26.31M

EPS, diluted

-$0.35

Free cash flow

-$26.50M
Reported periodTrailing twelve months

Press releases

Releases Vivani Medical filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Vivani Medical

Electromedical & Electrotherapeutic Apparatus

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that develops miniature, ultra long-acting subdermal drug implants. Using its proprietary NanoPortal technology, the company designs implants intended to provide reversible, near constant-rate delivery of therapeutic agents to treat chronic conditions such as obesity and type 2 diabetes. Its lead product candidate is NPM-139, a six-month semaglutide implant for chronic weight management. The company is also developing NPM-133, a semaglutide implant for type 2 diabetes, NPM-115, an exenatide implant for chronic weight management, and OKV-119, an implant for chronic weight management in companion animals developed in partnership with Okava Pharmaceuticals.

Company profile, executives and history

Vivani Medical stock: common questions

What is Vivani Medical's stock price?

VANI closed at $1.13 on Nov 11, 2026, down 1.74% on the day. Over the past 52 weeks it traded between $0.92 and $1.66.

What is Vivani Medical's market cap?

Vivani Medical was worth $101.93M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.

What is VANI's P/E ratio?

Vivani Medical lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.35), so it has no meaningful P/E ratio.

How much revenue does Vivani Medical make?

Vivani Medical reported revenue of $0 for fiscal 2025.

Does Vivani Medical pay a dividend?

No. Vivani Medical has not paid a cash dividend over the last twelve months.

When does Vivani Medical report earnings next?

Vivani Medical is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has VANI stock performed over the past year?

Including dividends, VANI returned -21.0% over the past year, against +12.4% for the S&P 500.

How many VANI shares are sold short?

0M shares were sold short at the latest FINRA report, 0.88% of the float, or 2.0 days of average trading volume.

Who are Vivani Medical's competitors?

Companies most similar to Vivani Medical by business, industry and size include ENDV, NRXS, CV, ECOR, INMD.

See a number that looks wrong?